Targeted Therapies in HER2-Positive Breast Cancer - A Systematic Review

Breast Care

Volumn 10, Issue 3, 2015, Pages 173-178

  Schramm, Amelie ^a   De Gregorio, Nikolaus ^a   Widschwendter, Peter ^a   Fink, Visnja ^a   Huober, Jens ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Dual HER2 blockade; HER2 positive breast cancer; Targeted therapies

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; LAPATINIB; PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC THERAPY;

EID: 84937889423     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000431029     Document Type: Review

References (38)

1. Mitri Z, Constantine T, O'Regan R: The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract 2012; 2012: 743193.
2. Graus-Porta D, Beerli RR, Daly JM, Hynes NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997; 16: 1647-1655.
3. Hynes NE, Stern DF: The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994; 1198: 165-184.
4. Ménard S, Tagliabue E, Campiglio M, Pupa SM: Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 2000; 182: 150-162.
5. Olayioye MA: Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res 2001; 3: 385-389.
6. Wolff AC, Hammond MEH, Hicks DG, Dowsett M, Mc-Shane LM, Allison KH, et al.: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 2014; 138: 241-256.
7. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, et al.: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66: 1630-1639.
8. Spector NL, Xia W, Burris H, Hurwitz H, Dees EC, Dowlati A, et al.: Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005; 23: 2502-2512.
9. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, et al.: The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1: 85-94.
10. Valabrega G, Montemurro F, Aglietta M: Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007; 18: 977-984.
11. Hudis CA: Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51.
12. Spector NL, Blackwell KL: Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009; 27: 5838-5847.
13. Nahta R, Hung M-C, Esteva FJ: The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004; 64: 2343-2346.
14. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, et al.: Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005; 23: 2534-2543.
15. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, et al.: Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28: 1138-1144.
16. Lynce F, Swain SM: Pertuzumab for the treatment of breast cancer. Cancer Invest 2014; 32: 430-438.
17. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al.: Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68: 9280-9290.
18. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al.: Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-1791.
19. Wong DJL, Hurvitz SA: Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates. Ann Transl Med 2014; 2: 122.
20. Brufsky AM: Current approaches and emerging directions in HER2-resistant breast cancer. Breast Cancer (Auckl) 2014; 8: 109-118.
21. Valabrega G, Montemurro F, Sarotto I, Petrelli A, Rubini P, Tacchetti C, et al.: TGFalpha expression impairs trastuzumab-induced HER2 downregulation. Oncogene 2005; 24: 3002-3010.
22. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M: Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009; 69: 9330-9336.
23. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
24. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM, et al.: 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 2013; 382: 1021-1028.
25. Perez EA, Romond EH, Suman VJ, Jeong J-H, Davidson NE, Geyer CE, et al.: Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29: 3366-3373.
26. Perez EA, Romond EH, Suman VJ, Jeong J-H, Sledge G, Geyer CE, et al.: Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 2014; 32: 3744-3752.
27. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, et al.: Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 2011; 29: 4491-4497.
28. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al.: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273-1283.
29. Crozier JA, Perez EA: Perspectives from the American Society of Clinical Oncology 2014 Conference: breast cancer highlights. Future Oncol 2014; 10: 1897-1899.
30. Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, et al.: Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015; 372: 134-141.
31. Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer J-U, et al.: Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxanebased chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012; 13: 135-144.
32. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al.: Lapatinib with trastuzumab for HER2-positive early breast cancer (Neo-ALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379: 633-640.
33. Gianni L, Pienkowski T, Im Y-H, Roman L, Tseng L-M, Liu M-C, et al.: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32.
34. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
35. Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, et al.: Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015; 372: 724-734.
36. Hurvitz SA, Dirix L, Kocsis J, Bianchi G V, Lu J, Vinholes J, et al.: Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2013; 31: 1157-1163.
37. Liedtke C, Thill M, Hanf V, Schütz F: AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2014. Breast Care (Basel) 2014; 9: 189-200.
38. Hanf V, Schütz F, Liedtke C, Thill M: AGO recommendations for the diagnosis and treatment of patients with advanced and metastatic breast cancer: update 2014. Breast Care (Basel) 2014; 9: 202-209.